Ritonavir

證據等級: L5

預測適應症: 3 個

One judgment call before drafting: predicted_indications[0] (feline AIDS) is TxGNN's top-ranked hit by array order, but the evidence pack's own repurposing_rationale flags it as a likely ontology-mapping artifact (human HIV trial, "grade C" relevance, no cat data) and predicted_indications[2] has zero evidence (L5, no mechanistic plausibility). Presenting either as the headline indication would misrepresent the evidence. I'm featuring rank 2 (SIV infection — L3, real mechanistic/experimental support) as the primary candidate and noting why the other two were screened out.

Ritonavir: From HIV-1 Infection to Simian Immunodeficiency Virus (SIV) Infection

One-Sentence Summary

Ritonavir is an HIV-1 protease inhibitor, used both as a direct antiretroviral and as a pharmacokinetic booster of other protease inhibitors via CYP3A4 inhibition. The TxGNN model's most biologically coherent prediction is Simian Immunodeficiency Virus (SIV) Infection — a lentivirus closely related to HIV-1 and a standard primate model for antiretroviral research — supported by 10 relevant publications including direct in vitro susceptibility data, though no dedicated clinical trials currently exist for this indication.

Note on model output: TxGNN also scored two other candidates at similarly high confidence — feline acquired immunodeficiency syndrome (rank 1) and a rare neurodevelopmental disorder (rank 3). Both were excluded from this report: the feline AIDS hit is annotated in the evidence itself as a likely disease-name mapping error (its only linked trial is a human HIV study), and the neurodevelopmental disorder has no mechanistic rationale, trials, or literature (L5, prediction-only).

Quick Overview

Item	Content
Original Indication	HIV-1 infection (per evidence-pack mechanistic annotation; no formal Finland label text on file)
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.92%
Evidence Level	L3
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation is not available in this evidence pack (flagged as a Blocking-severity data gap). Based on the information that is available, ritonavir is an HIV-1 protease inhibitor that also acts as a CYP3A4 inhibitor, a property exploited to raise the blood levels of co-administered protease inhibitors ("boosting"). Its efficacy against HIV-1 protease is well established.

SIV is a close relative of HIV-1 within the lentivirus genus and is widely used as an animal-model surrogate for HIV-1 in antiretroviral research. The evidence pack's own rationale for this prediction notes that PI-class drugs show cross-reactive inhibitory activity against SIV protease because of structural and substrate-specificity similarity between the two viral proteases — a claim borne out directly in the literature below (e.g., PMID 12709355 measured ritonavir's IC50 against SIV protease in vitro).

Because SIV infection is a research/model-organism condition rather than a target patient population, the practical value of this prediction is primarily as a validated tool compound use (confirming PI activity in SIV models for HIV cure/reservoir research) rather than a therapeutic indication in animals or humans — this distinction should guide how "Go/Hold" is interpreted downstream.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12709355	2003	In vitro susceptibility	Antimicrob Agents Chemother	Direct head-to-head comparison of PI susceptibility: SIVmac239 inhibited by ritonavir at EC50 ≈13 nM, similar to its potency against HIV-1 (EC50 ≈25 nM)
15040537	2004	In vitro susceptibility	Antiviral Therapy	Evaluated 16 approved anti-HIV-1 drugs against HIV-2, SIV (mac251, B670) and SHIV strains to inform treatment/PEP guidance
16973590	2006	Animal model (macaque)	Journal of Virology	Modeled rapid viral decay kinetics in SIVmac251-infected macaques on a 7-day quadruple antiretroviral regimen
25033210	2014	Animal model (macaque)	PLoS ONE	Combination ART plus the HDAC inhibitor SAHA tested in SIV-infected Chinese rhesus macaques as a viral-reservoir/cure model
12951220	2003	Animal model (macaque)	Journal of Virological Methods	Oral HAART including Lopinavir/Ritonavir given to SHIV(89.6P)-infected macaques; assessed impact on CD8+ T-cell subsets
34903055	2021	Animal model (macaque)	mBio	Found lentivirus (HIV/SIV) persistence in brain tissue despite effective ART, with neuroimmune activation
22737073	2012	Animal model (macaque)	PLoS Pathogens	Highly intensified multidrug ART tested across a range of viremia levels in SIVmac251-infected rhesus macaques; assessed viral reservoir restriction
17350308	2007	Basic virology	Microbes and Infection	Engineered a chimeric SHIV carrying HIV-1 protease as an in vivo tool for testing protease inhibitor efficacy in macaques
12186895	2002	Basic virology	Journal of Virology	Characterized viral-protease-dependent processing of the HIV-1 Vif protein within virions
9875393	1998	In vitro (unrelated compound)	Antiviral Chemistry & Chemotherapy	Fluoroquinolone derivative K-12 active against AZT- and ritonavir-resistant HIV-1 strains as well as HIV-2 and SIV

Finland Market Information

Ritonavir is not currently marketed in Finland; no marketing authorizations are on file (0 licenses recorded).

Safety Considerations

Please refer to the package insert for safety information. (Finland-specific warnings, contraindications, and drug-interaction data are recorded as a Blocking-severity data gap and were not retrievable from TFDA sources at this data cutoff.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence is limited to in vitro susceptibility assays and animal-model (macaque) studies using ritonavir only as part of combination ART — no study isolates ritonavir's effect or targets SIV infection as a primary clinical endpoint, and no dedicated clinical trials exist. Combined with the absence of Finland market presence and a Blocking-severity gap on core safety documentation, this candidate is not ready to advance past a research question.

To proceed, the following is needed:

Finland-specific package insert / SPC (warnings, contraindications, DDI) — currently Blocking data gap (DG001)
Confirmed mechanism-of-action documentation from DrugBank or equivalent (DG002)
Clarification of therapeutic intent: SIV infection is a research/animal-model condition, not a human or veterinary disease target — next step should define whether this is pursued as a tool-compound validation or reframed toward a clinically relevant lentivirus indication
Re-query TxGNN/ontology mapping for rank-1 (feline AIDS) to confirm or rule out the suspected disease-name mismatch before considering it further
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.